PhaseBio Pharmaceuticals, Inc. (PHAS) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

PhaseBio Pharmaceuticals, Inc. (PHAS) Healthcare & Pipeline Overview

PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company specializing in cardiovascular disease treatments, notably bentracimab, a reversal agent for ticagrelor. Currently under Chapter 11 reorganization, PhaseBio aims to address unmet needs in managing bleeding events and hypertension within the biotechnology sector.

What Is the Investment Thesis for PHAS?

PhaseBio Pharmaceuticals, Inc. presents a high-risk, high-reward investment profile, primarily due to its Chapter 11 reorganization. The potential value lies in the success of bentracimab (PB2452), currently in Phase III trials, which addresses a critical need for a ticagrelor reversal agent. Positive trial outcomes could significantly enhance its market value. However, the company's financial instability, evidenced by a profit margin of -1210.1% and ongoing bankruptcy proceedings, poses substantial risks. Successful restructuring and continued clinical progress are essential for PhaseBio to regain investor confidence and achieve long-term growth. The high beta of 2.87 indicates significant volatility, reflecting the speculative nature of its stock.

Based on FMP financials and quantitative analysis

PHAS Key Highlights

Bentracimab (PB2452) is in Phase III clinical trials, targeting patients with uncontrolled bleeding events or needing urgent procedures.

• The company filed for Chapter 11 bankruptcy on October 23, 2022, indicating financial instability.
• Gross margin is reported at 100.0%, though this is offset by a significantly negative profit margin of -1210.1%.
• The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. for PB2452.
• The company's beta is 2.87, indicating high volatility relative to the market.

Who Are PHAS's Competitors?

PHAS is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are PHAS's Key Strengths?

Novel drug candidates targeting unmet needs.

• Co-development agreement for PB2452.
• Focus on cardiovascular diseases.
• Experienced management team.

What Are PHAS's Weaknesses?

Chapter 11 bankruptcy.

• Limited financial resources.
• Dependence on clinical trial outcomes.
• High profit margin.

What Could Drive PHAS Stock Higher?

PHAS catalyst: Results from Phase III clinical trials for bentracimab (PB2452) are expected in the near term.

• Efforts to restructure the company's debt and financial obligations under Chapter 11.
• Potential for new partnerships or collaborations to support drug development.

What Are the Key Risks for PHAS?

Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.

• Chapter 11 bankruptcy proceedings pose a significant risk to the company's operations and financial stability.
• Failure to achieve positive results in clinical trials could halt the development of key drug candidates.
• Regulatory delays or rejection could impede the commercialization of new therapies.
• Competition from larger pharmaceutical companies with greater resources.

What Are the Growth Opportunities for PHAS?

• Successful Completion of Bentracimab Phase III Trials: The successful completion of Phase III clinical trials for bentracimab (PB2452) represents a significant growth opportunity. Positive results could lead to regulatory approval and commercialization, addressing the unmet need for a ticagrelor reversal agent. The market for reversal agents in cardiovascular procedures is estimated to reach $500 million by 2028, driven by the increasing use of antiplatelet drugs. This milestone is expected within the next 1-2 years, contingent on trial outcomes.
• Expansion into Pulmonary Arterial Hypertension (PAH) Treatment: PhaseBio's development of PB1046, a vasoactive intestinal peptide analogue for PAH, offers another growth avenue. The PAH market is projected to reach $7 billion by 2027, driven by advancements in treatment options and increasing diagnosis rates. Successful clinical development and commercialization of PB1046 could establish PhaseBio in this growing market segment. Clinical trials are ongoing, with potential for market entry within 3-5 years.
• Advancement of PB6440 for Resistant Hypertension: PB6440, PhaseBio's treatment for resistant hypertension, targets a significant patient population that does not respond to conventional therapies. The market for resistant hypertension treatments is expected to grow, driven by increasing awareness and diagnosis. Successful development and commercialization of PB6440 could provide a valuable revenue stream. Clinical development timelines are estimated at 3-5 years.
• Strategic Partnerships and Collaborations: Forming strategic partnerships with larger pharmaceutical companies or research institutions could provide PhaseBio with additional funding, expertise, and resources to accelerate its drug development programs. Collaborations could also expand the company's market reach and commercialization capabilities. The timeline for securing such partnerships is variable, but ongoing efforts are crucial for long-term growth.
• Restructuring and Financial Stability: Successfully navigating the Chapter 11 reorganization process is critical for PhaseBio's survival and future growth. Achieving financial stability through debt restructuring, asset sales, or new financing could restore investor confidence and enable the company to focus on its core drug development programs. The timeline for completing the reorganization process is uncertain, but a successful outcome is essential for unlocking the company's potential.

What Threats Does PHAS Face?

• Clinical trial failures.
• Regulatory hurdles.
• Competition from larger pharmaceutical companies.
• Economic downturn.

What Are PHAS's Competitive Advantages?

• Patented drug candidates provide exclusivity.
• Specialized expertise in cardiovascular drug development.
• Co-development agreement with SFJ Pharmaceuticals X, Ltd.
• Focus on addressing unmet medical needs.

What Does PHAS Do?

PhaseBio Pharmaceuticals, Inc., established in 2002 and based in Malvern, Pennsylvania, is a clinical-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for cardiovascular diseases. The company's primary focus is on addressing critical unmet needs in the treatment of life-threatening conditions. Its lead product candidate, bentracimab (PB2452), is a reversal agent designed for the antiplatelet drug ticagrelor. Bentracimab is currently in Phase III clinical trials, targeting patients experiencing uncontrolled major or life-threatening bleeding events, as well as those requiring urgent surgery or invasive procedures. In addition to bentracimab, PhaseBio is also developing PB1046, a vasoactive intestinal peptide analogue intended for the treatment of pulmonary arterial hypertension (PAH). Another product in their pipeline is PB6440, which is being developed for the treatment of resistant hypertension. PhaseBio has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to advance the development of PB2452. However, on October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, marking a significant challenge in its operational history.

What Products and Services Does PHAS Offer?

• Develop novel therapies for cardiovascular diseases.
• Focus on unmet needs in the treatment of life-threatening conditions.
• Develop Bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor.
• Develop PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension.
• Develop PB6440 for the treatment of resistant hypertension.
• Engage in clinical trials to evaluate the safety and efficacy of their drug candidates.

How Does PHAS Make Money?

• Develop and patent novel pharmaceutical products.
• Conduct clinical trials to demonstrate safety and efficacy.
• Seek regulatory approval from agencies like the FDA.
• Commercialize approved products through partnerships or direct sales.

What Industry Does PHAS Operate In?

PhaseBio Pharmaceuticals operates within the competitive biotechnology industry, which is characterized by high research and development costs, lengthy clinical trial processes, and stringent regulatory requirements. The market for cardiovascular disease treatments is substantial, driven by an aging population and increasing prevalence of conditions like hypertension and thrombosis. PhaseBio's focus on developing reversal agents and novel therapies positions it to address specific unmet needs within this market. However, the company faces competition from larger, more established pharmaceutical companies with greater resources and broader product portfolios. The industry is also influenced by evolving regulatory landscapes and reimbursement policies.

Who Are PHAS's Key Customers?

• Hospitals and medical centers.
• Cardiologists and other physicians.
• Patients with cardiovascular diseases.
• Pharmacies and distributors.

Company Profile

PhaseBio Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Malvern, US. The company is led by CEO Jonathan Mow. PHAS has traded publicly since 2018.

How PhaseBio Pharmaceuticals, Inc. Is Valued

Relative to its peer group, PHAS's quantitative score of 50/100 is below the peer average of 92/100.

Return on equity for PhaseBio Pharmaceuticals, Inc. stands at 0.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -0.2%, showing how much profit it generates from its asset base. A current ratio of 1.75 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -6.4%, the inverse of the P/E and a quick read on earnings relative to price.

PhaseBio Pharmaceuticals, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 14.2% below estimates on average.

PHAS Financials

PHAS Latest News

No recent news available for PHAS.

PHAS Analyst Consensus

PHAS MoonshotScore

Common Questions About PHAS (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources